How can we help you?
The paradigm of regenerative medicine development is changing. Our experienced team can help you stay on track.
We'll help you navigate and understand the emerging ISPOR/ISPE Real World Evidence guidelines.
Watch this webinar where our experts discuss different approaches for developing rigorous economic model structures for rare diseases.
This webinar, based on PRO labeling of cancer treatment drugs, examines trends in EMA and FDA labeling based on patient-reported outcomes (PROs).
Null hypothesis significance testing is not dead, but in this webinar you will learn why it ought to be.